The AMR Action Fund is a global public-private partnership that is focused on investing in the development of new antimicrobial therapeutics. With the rise of antimicrobial-resistant bacteria, which currently cause the deaths of approximately 1. 3 million people annually, the need for effective antibiotics has never been greater.

This fund aims to address this urgent challenge by supporting companies that are working to develop potentially life-saving antimicrobial drugs. The AMR Action Fund was conceptualized through discussions among renowned organizations such as the International Federation of Pharmaceutical Manufacturers and Associations, the World Health Organization, the European Investment Bank, and the Wellcome Trust. Its mission is to bring about breakthroughs in antimicrobials by investing in companies that are developing therapies for priority pathogens.

By fostering innovation and advocating for market reforms, the fund aims to facilitate the launch of two to four new antimicrobials by 2030, while establishing a sustainable investment ecosystem. In addition, the AMR Action Fund is committed to ensuring appropriate use and access to these drugs, collaborating with stakeholders to strengthen healthcare systems and create partnerships that support affordable access, particularly in low- and middle-income countries. Stay connected with the AMR Action Fund to stay updated on their progress in bringing new antibiotics to patients and combating antimicrobial resistance